Drugs / 3D185
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04221204 | Sep 2019 → Dec 2026 expected | cancer | 3D Medicines (Beijing) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05039892 | Dec 2026 → Dec 2027 expected | cholangiocarcinoma | 3D Medicines (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3D185 | “single oral dose of 3D185” NCT04221204 ↗ |
| Action | Inhibit | “Highly selective FGFR1-3 inhibitor” NCT04221204 ↗ |
| Route | Oral | “single oral dose” NCT04221204 ↗ |